Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Daily

Download Data

Theseus Pharmaceuticals Inc Share Price on February 23, 2024: USD 4.06

Theseus Pharmaceuticals Inc Share Price is USD 4.06 on February 23, 2024, a -56.53% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.

Theseus Pharmaceuticals Inc 52-week high Share Price is USD 11.82 on May 04, 2023, which is 191.13% above the current Share Price.
Theseus Pharmaceuticals Inc 52-week low Share Price is USD 2.12 on November 10, 2023, which is -47.78% below the current Share Price.
Theseus Pharmaceuticals Inc average Share Price for the last 52 weeks is USD 5.65.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends